We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Cordless Handheld Device Uses Vibrations to Eliminate Fingerstick Pain for Blood Sugar Testing

By LabMedica International staff writers
Posted on 10 Nov 2021
Print article
Image: DigiVibe Glucose Monitoring Device (Photo courtesy of BING Innovations, LLC)
Image: DigiVibe Glucose Monitoring Device (Photo courtesy of BING Innovations, LLC)

A new portable tool uses innovative vibration technology to improve the ease of diabetes management.

BING Innovations, LLC (Boca Raton, FL, USA) has launched DigiVibe, a cordless handheld device that uses vibrations to eliminate the pain of getting the finger pricked. Specifically designed for blood glucose monitoring, DigiVibe applies vibration directly to the finger, blocking pain signals to the brain and helping to make the process more tolerable for both children and adults.

While many people only get their finger-pricked at their annual checkup, for those with diabetes, glucose monitoring means having to prick their finger three or more times each day. DigiVibe, an FDA-registered and CE-certified device, has been created to reduce the pain and anxiety of checking glucose levels, whether a person is not keen on needles or just weary of repeated finger pricks. The easy-to-use and portable device adheres to any flat surface for hands-free use, making self-testing and diabetes management easier and more convenient than ever before. For a doctor who regularly deals with diabetic patients or an individual who must test their glucose levels regularly, the DigiVibe device can make the process easier and virtually painless - in as little as 12 seconds.

The DigiVibe Starter Kit includes a sleek carrying case containing one DigiVibe device, stand and tip, lancing device, five 30-gauge lancets, and one AA lithium battery. The battery is designed to last for approximately three months or roughly 450 finger sticks for a single user. Plus, there is enough space in the carrying case to fit one’s regular test strips and glucose testing device. Additional accessories or refills of supplies can also be ordered anytime on the DigiVibe website. One-time use disposable tips and lancing devices are also available for medical practitioners.

"The conventional way to test blood sugar for diabetes is often associated with pain, discomfort, and even fear, but DigiVibe has set out to dramatically make this experience better," said Dr. Marcelo Bendix, Endocrinologist and DigiVibe Medical Advisor. "Pain and finger soreness are among the top reasons diabetics sometimes skip blood glucose testing, which is not only dangerous, but makes it quite difficult for them to effectively manage diabetes. DigiVibe is truly a game-changer; it will allow patients to stay on top of their glucose testing and no longer fear the dreaded finger-prick they have to endure in the doctor's office and at home."

Related Links:
BING Innovations, LLC 

Gold Supplier
Nucleic Acid Extraction System
Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
Anti-SARS-CoV-2 Controls Kit
ACCURUN Anti-SARS-CoV-2 Controls Kit
Molecular Diagnostic Platform

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.